Combining CB-839 with Selumetinib (MEK inhibitor) takes advantage of the increased glutamine utilization in NSCLC cells with mutated KRAS to improve therapeutic efficacy (166). This evidence concerns the gene KRAS and non-small cell lung carcinoma.